Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Incyte has a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that INCY likely has seen a stronger improvement to ...
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the ...
Good morning, Boston. Here are the five things you need to know in local business news to start your busy, frigid Wednesday.
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 20 years ago, it would be worth $39,441.77 today based on ...
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...